TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00812123
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
Study: NCT00812123
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 x 1000mg, through level above 2ug/ml
Study: NCT01090700
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10 mg daily for 7 days
Study: NCT01090700
Drug: TMC435 + Escitalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TMC435 150 mg + escitalopram 10 mg daily for 7 days
Study: NCT01705145
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02417064
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will self-administer either 84 mg or 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
Study: NCT02417064
Drug: Duloxetine (Oral Antidepressant)
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
Study: NCT02417064
Drug: Escitalopram (Oral antidepressant)
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
Study: NCT02417064
Drug: Sertraline (Oral Antidepressant)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
Study: NCT02417064
Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
Study: NCT02136134
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered as an IV infusion or 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter. As per protocol amendment-6 participants receiving treatment with daratumumab IV will have the option to switch to daratumumab SC 1800 mg on Day 1 of any cycle, at the discretion of the investigator.
Study: NCT02136134
Drug: VELCADE (Bortezomib)
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
Study: NCT02136134
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
Study: NCT00312845
Drug: Bortezomib + Rituximab
Normalized name: Bortezomib
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
Study: NCT00312845
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
Study: NCT02453802
Drug: Tranexamic Acid 5%,5ml/amp
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
Study: NCT02453802
Drug: Tranexamic Acid 5%,5ml/amp
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
Study: NCT02453802
Drug: rivaroxaban (10mg)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
Study: NCT02214771
Drug: Fidaxomicin
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT02214771
Drug: Treatment for CDI other than fidaxomicin Type
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral
Study: NCT02383927
Drug: Tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTase inhibitor
Study: NCT01956955
Drug: enoxaparin ,alteplase, unfractionated heparin
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04538664
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.
Study: NCT04538664
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.
Study: NCT04538664
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.
Study: NCT04538664
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.
Study: NCT02918318
Drug: Intranasal esketamine (28 mg)
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
Study: NCT02918318
Drug: Intranasal esketamine (56 mg)
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
Study: NCT02918318
Drug: Intranasal esketamine (84 mg)
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
Study: NCT03345342
Drug: PP6M
Normalized name: Paliperidone Palmitate 6-Month
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive intramuscular injection of PP6M.
Study: NCT03345342
Drug: PP1M
Normalized name: Paliperidone Palmitate 1-Month
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
Study: NCT02437162
Drug: Ustekinumab 45 mg
Normalized name: ustekinumab 45 MG in 0.5 mL Injection
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 2.
Study: NCT02437162
Drug: Ustekinumab 90 mg
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 3.
Study: NCT02437162
Drug: Golimumab 50 mg
Normalized name: golimumab 50 MG in 4 mL Injection
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Groups 1, 2 and 3.
Study: NCT03981744
Drug: Ustekinumab 6 mg/kg
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
Study: NCT03981744
Drug: Ustekinumab 90 mg
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
Study: NCT02782104
Drug: Esketamine Nasal Spray
Normalized name: esketamine Nasal Spray
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
Study: NCT00811447
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m²/day intravenous
Study: NCT00811447
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m² or 75 mg/m² intravenous
Study: NCT00811447
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m² intravenous
Study: NCT01240954
Drug: OSIRIS other concentration 1
Normalized name: glycerin 1-methyl ether
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSIRIS new concentration 1
Study: NCT01240954
Drug: OSIRIS other concentration 2
Normalized name: 2-Hydroxyethyl phenyl ether
DrugBank: Phenoxyethanol (DB11304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OSIRIS new concentration 2
Study: NCT01334905
Drug: YM178
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT03185819
Drug: Midazolam Placebo Solution
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive placebo as oral dose to match midazolam drug.
Study: NCT04449133
Drug: AD128
Normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of two capsules before sleep for 7 days.
Study: NCT00644735
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00644735
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00396214
Drug: Bifeprunox
Normalized name: Bifeprunox
DrugBank: Bifeprunox (DB04888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
Study: NCT00396214
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.
Study: NCT00396214
Drug: Bifeprunox
Normalized name: Bifeprunox
DrugBank: Bifeprunox (DB04888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
Study: NCT00361842
Drug: CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Normalized name: irinotecan hydrochloride liposome Injection
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
Study: NCT03185819
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.
Study: NCT03185819
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive esketamine at a dose of 28 mg as intranasal solution.
Study: NCT03185819
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive esketamine at a dose of 56 mg as intranasal solution.
Study: NCT03185819
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive esketamine at a dose of 84 mg as intranasal solution.
Study: NCT04338321
Drug: Esketamine 28 mg
Normalized name: esketamine 28 mg nasal spray
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine will be self-administered at a dose of 28 mg as nasal spray.
Study: NCT04338321
Drug: Esketamine 56 mg
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine will be self-administered at a dose of 56 mg as nasal spray.
Study: NCT04338321
Drug: Esketamine 84 mg
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine will be self-administered at a dose of 84 mg (maximum uptitrated dose) as nasal spray.
Study: NCT04338321
Drug: Quetiapine XR 50 mg
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR will be administered at an initial dose of 50 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
Study: NCT04338321
Drug: Quetiapine XR 100 mg
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR will be administered at a dose of 100 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
Study: NCT04338321
Drug: Quetiapine XR 150 mg
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR will be administered at a dose of 150 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
Study: NCT01077622
Drug: ofatumumab 100 mg, 1000 mg / vial
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
Study: NCT01260142
Drug: Fospropofol disodium, propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
Study: NCT02438787
Drug: Ustekinumab 45 mg
Normalized name: ustekinumab 45 MG in 0.5 mL Injection
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
Study: NCT01260142
Drug: Fospropofol disodium, propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
Study: NCT01260142
Drug: Fospropofol disodium, propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
Study: NCT02438787
Drug: Ustekinumab 90 mg
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
Study: NCT02438787
Drug: Golimumab 50 mg
Normalized name: golimumab 50 MG in 4 mL Injection
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
Study: NCT03412565
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
Study: NCT03412565
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered as 1.3 mg/m\^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
Study: NCT03642288
Drug: Gastrografin
Normalized name: Gastrografin
DrugBank: Diatrizoate (DB00271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with CRE-induced SBO or ASBO both received GG challenge.
Study: NCT03412565
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
Study: NCT03412565
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.
Study: NCT03412565
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan will be administered as 9 mg/m\^2 orally in Cycles 1 to 9.
Study: NCT03412565
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone will be administered as 60 mg/m\^2 orally in cycles 1 to 9.
Study: NCT03412565
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib will be administered as 20 mg/m\^2 IV on Day 1 of Cycle 1 only then 70 mg/m\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
Study: NCT03379311
Drug: AK002
Normalized name: MONOCLONAL ANTIBODY AK002
DrugBank: Lirentelimab (DB16728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
Study: NCT01119534
Drug: Guaiacol, eucalyptol, menthol and camphor suppository
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 times per day
Study: NCT01119534
Drug: guaiacol suppository
Normalized name: guaiacol
DrugBank: Guaiacol (DB11359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 times per day